ArticleNeurology and therapy2026
Practical Guidance for Initiation and Management of Patients on Once-Nightly Sodium Oxybate for Narcolepsy Treatment: Modified Delphi Panel Consensus Recommendations.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite its strong recommendation for treatment of excessive daytime sleepiness (EDS), cataplexy, and disease severity associated with narcolepsy by the American Academy of Sleep Medicine, sodium oxybate (SXB) remains underutilized. Once-nightly SXB (ON-SXB) is an extended-release formulation of SXB approved for treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. ON-SXB has only been commercially available since 2023; thus, additional practical clinical recommendations may be helpful.
methodsSeven advanced practice providers (APPs) who practice sleep medicine were invited to participate in a modified Delphi panel to develop practical recommendations for the management and initiation of ON-SXB in patients with narcolepsy. Panelists addressed six themes: managing expectations and patient education, dosing and titration, discontinuation and adherence, transitioning from twice-nightly oxybates (TN-OXB), polypharmacy, and sodium. Panelists first answered open-ended questions, then met virtually to discuss responses and seek consensus. Topics not reaching consensus were fielded to the panelists via iterative rounds of questionnaires and virtual meetings.
resultsPanelists recommended that clinicians set expectations for treatment, side effects, and frequent communication with oxybate-naive patients. Indicators of medication discontinuation (e.g., missed follow-up appointments, late/missed refills, patients needing "coaching" to continue medication) were identified. For patients switching from TN-OXB, questions were proposed to determine effects of the second nightly dose on the patient and family/partner. After determining readiness to modify concomitant narcolepsy treatments, stimulants were recommended as the first medication to adjust. Consensus was achieved that discussions about sodium should be relevant to the patient's existing cardiovascular risk and occur in the context of the benefits of consolidated sleep.
conclusionAPPs have a unique and pragmatic experience in treating people with narcolepsy. Delphi consensus recommendations drawn from their experience may inform the approach to ON-SXB use in narcolepsy and help clinicians optimize patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.